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As the average life expectancy of patients with cystic fibrosis (CF) improves, the long 
term co-morbidities assume increasing importance. CF related diabetes (CFRD) has 
adverse effects on both nutrition and pulmonary function, and is associated with 
increased mortality. Abnormalities of glucose metabolism in CF represent a 
continuum; however the predominant abnormality is postprandial, not pre-prandial, 
glycaemia. Insulin is currently recommended as the treatment of choice for CFRD, 
but its use is associated with a number of limitations, including hypoglycaemia. Both 
the rate of gastric  emptying  and  the  consequent  release  of  the  ‘incretin’  hormones,  
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-1 
(GLP-1), from the gut are important determinants of overall glycaemic control, 
particularly postprandial glycaemia. Both are abnormal in conditions associated with 
exocrine pancreatic insufficiency. Incretin based therapies that have the capacity to 
slow gastric emptying and/or modulate the  release  of  ‘incretin’  hormones,  are  now  
used widely in type 2 diabetes (T2D). This paper explores the determinants of 
glycaemic control in CF, with a particular focus on the roles of gastric emptying and 
‘incretin’  hormones,  providing  a  rationale  for  the use of therapies that delay gastric 
emptying, including incretin mimetics, to minimise postprandial glycaemia and 










The establishment of specialised CF centres, and substantial nutritional and 
pharmaceutical advances during the last 60 years, have improved mean life 
expectancy for CF by more than 38 years, with the consequent clinical challenge of 
prevention and management of long-term co-morbidities, of which CFRD has 
increasing prominence [1]. The abnormalities of glucose metabolism in CF represent 
a continuum from normal, through pre-diabetes, to overt diabetes with the 
pathogenesis characterised by postprandial, rather than pre-prandial, 
hyperglycaemia. Insulin is currently the treatment of choice for CFRD although the 
acceptance and compliance with this therapy is challenging due to the already high 
burden of care in the CF population. Newer therapies are available that specifically 
modify postprandial glycaemia, such as those based on the incretin system, which 
are widely utilised in the management of T2D. These therapies may represent a 
logical treatment for CFRD, as monotherapy or in combination with basal insulin, as 
they specifically address postprandial hyperglycaemia. 
 
CFRD Prevalence and Significance  
The prevalence of CFRD increases with age, such that more than 50% of 
patients over 40 years are affected [2]. The mortality rate for CFRD has been 
estimated at 3.5 per 100 person years, from a peak 20 years ago of 6.2 per 100 
person years, but remains substantially higher than in CF patients without diabetes 
[2]. This improvement is largely due to increased awareness and detection in the 
pre-diabetic state, which is imperative in light of persuasive evidence that the optimal 
management and long-term prognosis of CF, is affected greatly by the presence of 
carbohydrate intolerance. The long term implications of CFRD for pulmonary health 
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and body mass index (BMI) are considered of greater relevance than the 
microvascular and macrovascular complications classically associated with type 1 
diabetes (T1D) and T2D, although with increased survival microvascular 
complications have now become apparent, as will be discussed. CFRD with fasting 
hyperglycaemia is associated with a decline in pulmonary function and nutrition, an 
increase in the incidence of Pseudomonas aeruginosa and Burkholdaria cepacia 
infection, doubling of hospitalisation rates, and an increase in the prevalence of liver 
disease [3]. CFRD also adversely affects prognosis after lung transplantation [4].  
Whether these associations are a direct effect of CFRD, or reflect more severe 
disease is uncertain; however the degree of clinical decline, particularly in respiratory 
function, correlates directly with glycaemic control. Moreover, there is now 
persuasive evidence that the decline in nutritional and pulmonary status occurs 2- 6 
years before the diagnosis of CFRD, when postprandial hyperglycaemia is less 
marked [5, 6].  This  suggests  that  even  ‘early’  carbohydrate intolerance, with 
relatively modest postprandial glycaemic excursions, is metabolically detrimental to 
pulmonary function. Upper airway glucose concentrations are higher in CF when 
compared with healthy subjects, and those with T1D or T2D, with the potential to 
facilitate bacterial growth and subsequent lung damage [7]. Direct toxic effects of 
hyperglycaemia on airway function remain to be established. 
Microvascular complications occur in CFRD, albeit with a lower prevalence 
than in T1D or T2D, and are related both to the duration of diabetes and glycaemic 
control. Ten years from the diagnosis of CFRD, 50% of patients are reported to have 
peripheral neuropathy, 16% retinopathy and 14% microalbuminuria [8]. 
Macrovascular complications in CFRD have not featured in the literature, possibly 
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reflecting both the shorter life expectancy and beneficial effect conferred by the 
genetic mutation and fat malabsorption. 
 
CFRD Pathogenesis  
The pathogenesis of CFRD is multifactorial, with both the CF genotype and 
innate and adaptive immunity contributing to ß cell destruction [9, 10]. CFRD is 
characterised by predominantly postprandial, rather than pre-prandial, 
hyperglycaemia. This contrasts with T1D, and the proportional elevation of 
postprandial glucose in CF, relative to fasting glucose, is greater than in T2D. The 
primary defect has been regarded as insulin deficiency, with a variable contribution 
from insulin resistance, dependent on clinical state, infection, inflammation and 
concurrent steroid medication. There is, however, a poor correlation between clinical 
diabetes and the degree of islet cell damage, suggesting that other factors, such as 
autoimmunity, may be involved. However, the prevalence of islet antibodies and T1D 
susceptibility alleles in CFRD appear to be comparable to the general population, 
although CFRD and T1D co-exist in a minority [11]. It has been suggested that 
CFRD may be more closely related to T2D, with islet amyloid deposits, as seen in 
T2D, being evident in 69% at autopsy [12]. It is not clear whether amyloid deposits 
play a direct role in the pathogenesis of ß cell death or are simply a marker of 
increasing ß cell stress [13, 14]. Susceptibility genes that increase the risk of T2D in 
the general population have been found in CFRD, strongly suggesting these genes 
may increase the propensity to diabetes in CF, and a family history of T2D increases 
the risk of CFRD substantially [11]. 
The cystic fibrosis transmembrane conductance regulator (CFTR) protein may 
play a direct role in insulin secretion. Ivacaftor, a CFTR potentiator, is a new therapy 
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which improves chloride transport through the dysfunctional CFTR protein in 
individuals with the G551D mutation. The implications for glycaemic control are 
uncertain; however in a pilot study of 5 CF patients Ivancafor improved insulin 
secretion, albeit without affecting glycaemic control [15].   
 
CFRD Diagnosis  
Carbohydrate intolerance in CF represents a continuum on which patients fluctuate, 
depending on clinical variables including infection, energy requirement, nutritional 
state, gastrointestinal absorption and steroid therapy. The diagnosis of CFRD is 
challenging, not just because of this intra-individual variability, but also because of 
the  lack  of  a  ‘gold  standard’  diagnostic  test.  In  practice,  carbohydrate intolerance in 
CF is commonly classified into categories of normal glucose tolerance, indeterminate 
glucose tolerance, impaired glucose tolerance, CFRD without fasting 
hyperglycaemia, and CFRD with fasting hyperglycaemia (Table 1) based on an oral 
glucose tolerance test (OGTT, 1.75g/kg body weight, maximum 75g) using fasting 
and 120 minute glucose levels [2]. 
Categories 
 
Fasting plasma glucose 
(mmol/L) 
2hr plasma glucose 
(mmol/L) 
Normal glucose tolerance <7.0 <7.8 
Indeterminate glucose 
tolerance 





CFRD without fasting 
hyperglycaemia 
<7.0 ≥11.1 
CFRD with fasting 
hyperglycaemia 
≥  7.0 OGTT not necessary 
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Table 1. Categories of carbohydrate intolerance in CF by OGTT.  
 
Previously, the OGTT was regarded as the diagnostic gold standard with high 
sensitivity [16]; however more recent evidence indicates that many patients 
experience large glycaemic excursions at 30, 60 and 90 minutes after oral glucose, 
which may be clinically significant, but have normal blood glucose levels at baseline 
and 2 hours [17]. While there is a relationship between the 2 hour OGTT blood 
glucose value and glycaemic excursions following a mixed meal in healthy subjects, 
and those with impaired glucose tolerance or overt diabetes [18], the absolute blood 
glucose concentrations vary substantially between the two tests. The OGTT tends to 
elicit greater glycaemic excursions, while a mixed meal more accurately represents 
the glycaemic variations occurring in everyday life. In CF, this is particularly 
important, since exocrine pancreatic insufficiency may influence the response to a 
mixed meal, but not to oral glucose. Moreover, unless blood glucose is measured 
more frequently than at 2 hours (eg. every 30 min), the OGTT may miss an early 
glycaemic peak. The OGTT also has poor specificity, with up to 58% of patients with 
impaired glucose tolerance being shown to revert to normal glucose tolerance and 
only 14% progressing to CFRD over the following 5 years [19]. Measurement of 
insulin and C-peptide responses to an OGTT may aid in detecting abnormalities in 
carbohydrate metabolism and progression. A delayed and reduced insulin peak and 
first phase insulin response to oral and intravenous glucose tolerance tests are 
evident in CF subjects with impaired, compared with those with normal glucose 
tolerance [20]. This information may facilitate identification of those at high risk of 
progressing to CFRD however more studies are required. HbA1c cannot be used to 
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screen for CFRD, as levels are often falsely normal in CF and do not reliably 
correlate with glycaemic control.  
 
CFRD Current Management  
The 2009 International Society for Pediatric and Adolescent Diabetes (ISPAD) 
clinical practice guidelines for the management of CFRD recommend a combination 
of basal (long-acting) and bolus (rapid-acting) insulin [21]. Pump insulin therapy 
offers the greatest flexibility and a reduction in the number of injections required [22]; 
however  insulin  regimens  need  to  take  into  consideration  the  patients’  individual  
needs and current treatment burden. Basal insulin doses start around 0.25u/kg/24h 
and are titrated to fasting blood glucose levels with suggested pre-meal insulin doses 
of 0.5-1u  per  15g  of  carbohydrate  and  ‘correction’  doses  added  as  required  [21].    
   While a basal-bolus insulin regimen is recommended, a 2013 Cochrane 
review was unable to identify sufficient evidence to inform on the optimal 
management of hyperglycaemia in CF [23]. The relative benefits of postprandial, 
versus pre-prandial, glycaemic control have not been evaluated in CF; however in 
T2D it is now recognised that postprandial glycaemic excursions are a major 
determinant  of  ‘overall’  glycaemic  control,  particularly  in  the  lower  range  of  HbA1c. 
The best management of CFRD without fasting hyperglycaemia and impaired 
or indeterminate glucose tolerance also remains unclear, and determining the 
optimal therapy for pre-diabetes is regarded as an urgent priority by the CF 
Foundation, American Diabetes Association and Pediatric Endocrine Society [24]. 
The outcomes of several studies indicate insulin therapy can ameliorate the decline 
in pulmonary function and BMI seen in the early stages of impaired glucose 
tolerance [5, 6]. In adults, an 8% increase in FEV1 and 42% decline in pulmonary 
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exacerbations were evident during 12 months of basal insulin (Glargine) therapy [6], 
with reversal of chronic weight loss [5].  These  effects  are  attributable  to  insulin’s  
anabolic role, increasing protein synthesis and BMI with enhanced respiratory 
muscle strength, rather than a direct effect of improved glycaemic control. 
It is well recognised that it can be difficult to achieve satisfactory glycaemic 
control in CF subjects using insulin therapy. Not infrequently, the therapeutic 
emphasis has been on pre- rather than postprandial glycaemic control. In 
determining the optimal insulin regimen and maximising compliance, current 
therapies and social supports, need to be taken into consideration. Because insulin 
therapy is invasive, requires regular injections, and is associated with a high risk of 
hypoglycaemia, acceptability of this therapy in the early stages of carbohydrate 
intolerance, or indeed even in overt CFRD, is likely to be limited. There are few 
established alternative therapeutic options, given traditional oral hypoglycaemic 
agents are not currently recommended in CF due to limited data and the risk of 
adverse effects [23]. Metformin is associated with gastrointestinal side effects, has a 
theoretical risk of lactic acidosis, and is better suited to obese patients with insulin 
resistance. Sulphonylureas increase insulin secretion, but bind to the CF 
transmembrane conductance regulator, raising concerns they may interfere with 
other CF therapies. Thiazolidinediones primarily target peripheral insulin resistance, 
which is not the dominant feature in CFRD. 
Glycaemic control in this population is further challenged by states of 
increased insulin resistance such as acute pulmonary infection and pregnancy, and 
following lung transplantation. Medications, such as corticosteroids, given during an 
acute pulmonary exacerbation, combined with increased insulin resistance can result 
in a temporary requirement for exogenous insulin. In those with CFRD acute 
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infection may increase insulin requirements 4 fold [21]. With resolution of the 
infection requirements typically return to previous levels.  
During pregnancy, insulin resistance increases, putting women with CF at 
greater risk of developing gestational diabetes when compared to healthy females. 
Monitoring of blood glucose at routine appointments, an OGTT on confirmation of 
pregnancy (if one has not occurred the prior 6 months), and at the end of the 1st and 
2nd trimester, is recommended [24]. 
Lung transplantation does not appear to increase the risk of diabetes in CF 
patients compared with non-CF transplant patients [25]; however glycaemic control 
deteriorates in the majority of CFRD patients following transplantation [26].  
Hypoglycaemia can occur in CFRD in the context of insulin therapy, although 
normal hypoglycaemic awareness is generally maintained. Education is paramount 
in reducing the risk. The non-diabetic CF population may have a greater tendency to 
fasting hypoglycaemia than the healthy population [27]. 
 
DETERMINANTS OF GLYCAEMIA IN CF 
 Key determinants of postprandial glycaemic control in CF include gastric 
emptying, gut hormone secretion (particularly the incretins, GIP and GLP-1, but also 
cholecystokinin (CCK) and peptide tyrosine tyrosine (PYY)), the insulin and glucagon 
response, pancreatic enzyme supplementation and the high fat/ high energy diet 
recommended for these patients. Gastric emptying and incretin hormone secretion 
are central to postprandial glycaemic control [28]; but have received little attention in 
CF.  
 
Gastric emptying in health and CF 
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In health, individual gastric emptying rates vary substantially between 1-4 
kcal/min [29], with regulation predominantly arising through inhibitory feedback 
triggered by carbohydrate, protein and fat digestion in the small intestine. The 
presence of lipolytic products in the intestinal lumen contributes substantially to the 
neurohumoral feedback mechanisms that slow gastric emptying. The use of the  
lipase inhibitor, orlistat, in T2D is associated with accelerated gastric emptying and 
accentuation of postprandial hyperglycaemia [30]. The rate of gastric emptying is in 
turn a fundamental determinant of the release of gut peptides and the rate of 
carbohydrate absorption, both of which are central to postprandial glycaemic control. 
Gastric emptying accounts for around one third of the variation in peak glucose 
response after an oral glucose load in health or T2D [31]. Relatively more rapid 
gastric emptying (3-4kcal/min) is associated with a greater initial rise in blood 
glucose, while slower emptying (<1.5kcal/min) provides a more controlled rise [32].  
Multiple variables may influence the rate of gastric emptying, including meal 
composition and volume, posture, illness, glycaemia and medications. Variables of 
particular relevance to CF are pancreatic enzyme supplementation, glycaemia and 
the high fat/ high energy diet prescribed for these patients. Exocrine pancreatic 
insufficiency affects around 80% of CF patients and requires pancreatic enzyme 
supplementation; however, the latter fails to normalise fat absorption in around 20% 
[33]. The relationship between gastric emptying of nutrients and supplemental 
enzymes is complex, and co-ordination of both to optimise nutrient absorption is 
therapeutically challenging, particularly when gastric emptying is disordered (either 
abnormally fast or slow) [33, 34]. It is recognised that there is substantial inter-
individual variation in gastric emptying of food and enzymes respectively, with 
enzymes empting on average 60 minutes before food when given together [35].  
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Meal composition and the size of spheres in enzyme formulations are important. 
Mixing of enzymes with the liquid component of a meal can result in rapid non-
parallel emptying, given that liquids empty more rapidly than solids. There is 
inconsistent information in relation to the impact of the size of the enzyme sphere on 
the  rate  of  emptying;;  however,  smaller  spheres  (≤1mm)  generally  empty  more  
rapidly,  and  emptying  of  spheres  ≥1.6mm  may  be  delayed  up  to  3  hours  after  a  meal  
[34]. Pancreatic enzyme efficacy is further impaired in CF by a lower intestinal pH, 
due to impaired HCO3 secretion, resulting in delayed dissolution of the enteric 
coating on enzyme formulations [36]. 
Gastric emptying is itself influenced by acute changes in blood glucose 
concentrations, with hyperglycaemia delaying gastric emptying, which in turn slows 
the absorption of ingested carbohydrate and reduces the propensity for further 
hyperglycaemia [37]. Conversely, in health and T1D, insulin-induced hypoglycaemia 
accelerates emptying, increasing the delivery of nutrients to the small intestine, and 
again providing an adaptive response [38]. 
The high fat diet prescribed in CF would be expected to favour slow gastric 
emptying, since fat is a potent inhibitor of emptying. However, ingestion of a diet high 
in fat in healthy subjects is associated with relatively more rapid emptying of fat, 
presumably reflecting a reduction in small intestinal inhibitory feedback [39]. In 
patients with CF, the majority of whom have pancreatic exocrine insufficiency, the 
emptying of high fat meals is further complicated by fat maldigestion, an issue which 
is discussed in detail subsequently. Protein, such as whey, has been shown to slow 
gastric emptying through enhanced gut hormone secretion [40]. Digestion of protein 
is also impaired in pancreatic insufficient CF, although to a lesser degree than fat, 
which may contribute to rapid gastric emptying in CF.  
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Despite the potential importance of abnormal gastric emptying in CF patients, 
only a limited number of studies have evaluated gastric emptying in this population 
[33, 41-45], with inconsistent results, attributable to differences in subject 
characteristics, meal composition, use of pancreatic enzymes and the method used 
to measure gastric emptying. Studies have reported abnormally rapid [41, 42] or 
delayed [44] emptying, or no difference from controls [33, 43, 45]. A bimodal pattern 
of  gastric  emptying  has  also  been  proposed,  with  more  rapid  emptying  ‘early’  in  the  
disease reflecting gut adaptations to the high energy diet, and delayed emptying 
‘later’,    when  malnutrition  is  more  likely  to  be  present  [42]. Rapid gastric emptying 
has been shown in exocrine pancreatic insufficiency from other causes, such as 
chronic alcoholism [46].  
There is no consistent evidence of abnormal gastric musculature or 
innervation altering gastric emptying in CF; therefore it may be reasonable to 
conclude that gastric emptying in CF with exocrine pancreatic insufficiency, in the 
absence of enzyme replacement, will be more rapid due to fat malabsorption, since 
fat is crucial in regulating gastric emptying. In a small study of adults with CF we 
demonstrated rapid emptying of a high fat/ carbohydrate meal, associated with 
marked postprandial hyperglycaemia. Pancreatic enzyme supplementation slowed 
gastric emptying and markedly decreased the postprandial glycaemic excursion 
(Fig.1-2) [41]. We recently reported the same phenomenon in a study of 14 
paediatric CF patients (Fig.3) [45]. 
 
Gut hormone secretion  
The  “incretin”  hormones,  GLP-1 and GIP, are secreted from intestinal L and K 
cells respectively in response to nutrient digestion and exposure [47] and are rapidly 
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degraded by the enzyme dipeptidyl peptidase-4 (DDP-4)  to  form  ‘inactive’  
metabolites. Up to 70% of the total insulin response to oral glucose can be attributed 
to the actions of GLP-1 and GIP, making these peptides critical to postprandial 
glycaemic control [47]. GLP-1 improves postprandial glycaemia through slowing 
gastric emptying and its glucose-dependent insulinotropic and glucagonostatic 
properties. GIP is insulinotropic, and can stimulate, rather than suppress, glucagon 
secretion, but appears not to affect gastric emptying [48]. Both the nutrient load and 
the rate at which nutrients empty to the small intestine are fundamental determinants 
of GLP-1 and GIP secretion. With increasing rates of small intestinal glucose 
exposure, there is a linear increase in GIP secretion. By contrast, GLP-1 secretion is 
minimal at low rates (<2kcal/min) of glucose exposure, but increases substantially at 
higher rates (3-4kcal/min) in both health and T2D [32].  
CCK and PYY may also influence postprandial glycaemic control through 
inhibition of gastric emptying, with their release also being dependent on nutrient 
digestion. CCK is released from I-cells in the duodenum and PYY predominantly by 
the L cells in the distal small intestine and colon, both in response to fatty acids, 
amino acids and glucose.  
Based on the above, it may be anticipated in CF, associated with untreated 
pancreatic insufficiency, that meal induced secretion of GLP-1, GIP, CCK and PYY 
would be impaired. No studies have evaluated CCK or PPY in CF, and evidence 
relating to GLP-1 and GIP secretion is limited and conflicting, probably reflecting 
methodological inconsistencies [41, 49]. Our recent work, in both adult and 
paediatric CF patients, has provided persuasive evidence of a marked reduction in 
GLP-1 and GIP secretion in response to a high fat/high carbohydrate meal [41, 45].  
Pancreatic enzyme supplementation restored GLP-1 and GIP secretion, though the 
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latter was still not normalised in the adult group (Fig.2), perhaps suggesting 
suboptimal mixing of enzymes and nutrients in the most proximal small intestine, 
from which most of GIP is derived.   
 
Insulin secretion and action  
That CFRD represents a state of insulin deficiency is evidenced by the loss of 
1st phase insulin secretion, characterised by a delay of at least 60 minutes in the 
insulin response to a meal when compared to health, together with a reduction in 
peak insulin levels [49, 50]. 1st phase insulin secretion is critical to the regulation of 
postprandial glycaemia, and in CF, impairment is evident in early stages of abnormal 
carbohydrate metabolism including some with a normal OGTT [50]. Insulin 
resistance as assessed by homeostatic model assessment (HOMA-IR), is also 
evident in CFRD, but probably plays a lesser role in postprandial glycaemic control, 
and assumes greater importance during infection, or treatment with corticosteroids. 
Dysregulation of glucagon secretion may occur in CF, as a result of damage to 
pancreatic  α  cells  [49, 50]. A diminished glucagon response to insulin-induced 
hypoglycaemia is evident in pancreatic insufficient CF subjects [50]; conversely, an 
impaired capacity to suppress glucagon in response to oral glucose is increasingly 
evident as carbohydrate tolerance worsens [49]. Increases in insulin clearance, 
hepatic gluconeogenesis and glucose absorption may also contribute to glycaemic 
dysregulation in CF.  
 




 Many of the current recommendations for the management of CFRD are 
based on expert consensus, due to the lack of higher levels of evidence and the 
limited therapeutic options available [51]. The pathogenesis of abnormal 
carbohydrate metabolism in CFRD, particularly in the early stages, is dominated by 
postprandial, not pre-prandial hyperglycaemia, so the former should logically be the 
dominant therapeutic focus. Therapies that target postprandial hyperglycaemia may 
act by modifying gastric emptying and/or incretin hormone secretion; in particular, 
pancreatic enzyme  supplementation,  the  use  of  macronutrient  ‘pre-loads’,  and  
incretin-based therapies, particularly GLP-1 agonists, may be of relevance in CF. 
There may also be additional benefit in combining these therapies with basal insulin 
to target postprandial and pre-prandial hyperglycaemia respectively. The 
combination of basal insulin with a GLP-1 agonist represents an approach attracting 
increasing attention in the management of T2D [52]. 
 
Pancreatic Enzyme Supplementation  
Optimising pancreatic enzyme supplementation, through adequate dosing and 
timing of administration, is an important first step in achieving postprandial glycaemic 
control, with improved fat digestion stimulating gut hormone secretion and 
attenuating any tendency for rapid gastric emptying [41]. In the early stages of 
carbohydrate intolerance, this alone may be an effective management strategy. 
Pancreatic enzymes given prior to a meal at a dose appropriate for the fat content 
(500-4000IU lipase/gram of dietary fibre, mean 1800IU lipase/gram of fat/meal, 
maximum 10,000u lipase/kg/day [53]) would be a reasonable starting point, with 
efficacy assessed by postprandial blood glucose concentrations, particularly at 30 
and 60 minutes. Dosing based on body weight alone is simpler; however dosing 
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based on  the  meal  fat  content  is  more  likely  to  replicate  the  body’s  normal  response.  
Combination therapy with a proton pump inhibitor, reducing duodenal acidity, may 
further optimise pancreatic enzyme efficacy. Additional information is required 
particularly regarding further therapeutic benefits of increased doses, and optimal 
timing in relation to the meal.  
 
Potential Future Research 
Macronutrient  ‘pre-load’. 
The  novel  ‘pre-load’  concept  is  currently  being  explored  in  T2D  for  the  management  
of postprandial hyperglycaemia. A macronutrient pre-load is consumed 30-60 
minutes prior to a meal to prime neurohumoral feedback, resulting in pre-emptive 
slowing of gastric emptying and increased incretin hormone secretion. A fat pre-load, 
known to be potent in slowing gastric emptying, appears to have only a limited effect 
on overall postprandial glycaemia in T2D [54]. In contrast, acute administration of a 
whey protein preload slows gastric emptying, stimulates incretin hormones, and 
markedly increases insulin secretion, probably predominantly via amino acids, 
thereby markedly reducing postprandial glycaemia [40]. The increase in calorie 
consumption  with  a  ‘pre-load’,  a  potential  disadvantage  in  T2D,  would  not  be  an  
issue in CF; however the current CF dietary prescription of 3 meals and 3 snacks per 
day  make  a  ‘pre-load’  less  feasible.  Further  studies  assessing  the  optimal  quantity,  
timing and long term benefits, in particular the effect of a protein pre-load before the 
main meals in CF is required.  
Incretin-based therapies. 
Incretin-based therapies, particularly GLP-1 agonists, are effective in the 
management of T2D [52]. The half-life of subcutaneously administered GLP-1 
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agonists  appears  to  dictate  whether  efficacy  is  primarily  preprandial  (‘non-prandial’)  
or postprandial (‘prandial’).  ‘Prandial’  agonists  (exenatide,  lixisenatide)  have  a  short  
duration of action, exerting a greater effect on postprandial glycaemia, predominantly 
through potent slowing of gastric emptying and postprandial insulin suppression [55]. 
‘Non-prandial’  agonists  (liraglutide  and  exenatide  LAR),  are  longer  acting  and  better  
suited for pre-prandial glycaemic control, since their predominant mode of action is 
to stimulate insulin and suppress glucagon secretion [56]. The mechanisms 
underlying glucose-lowering  induced  by  ‘prandial’  GLP-1 agonists suggest potential 
benefits even in the early stages of the continuum of abnormal carbohydrate 
metabolism in CF; however this remains uninvestigated. The combination of a GLP-1 
agonist for control of postprandial glycaemia, in conjunction with basal insulin for pre-
prandial glycaemic control, is being used to good effect in T2D [57] .This therapeutic 
combination may provide more effective pre- and postprandial glycaemic control in 
CFRD with fasting hyperglycaemia than insulin therapy alone, and should be 
explored further.  
Adverse effects associated with GLP-1 agonists, include gastrointestinal symptoms 
and modest weight loss, both of which would of concern in the CF population. In T2D 
however, only a minority of patients cannot tolerate therapy due to nausea, 
particularly if the dosage is increased gradually [58]. It is not known whether GLP1 
agonists affect body weight in those with a normal or low BMI. Furthermore rates of 
obesity (BMI>30kg/m2 in adults), previously not considered an issue in CF, are now 
increasing in CF centres in Europe, the USA and Australia [59-61]. Recent concerns 
relating to the potential association of incretin-based therapies with pancreatitis and 
pancreatic cancer have diminished [62] but need to be recognised, particularly in this 




The pivotal roles of pancreatic enzyme therapy, gastric emptying and incretin 
hormones in the pathophysiology of CFRD, characterised by postprandial 
hyperglycaemia, has largely been ignored. New therapies that act on gastric 
emptying and the incretin axis should be of considerable interest in the management 
of postprandial glycaemia in CF. With a high priority being given to finding 
appropriate and acceptable therapies for pre-diabetes and CFRD, the optimisation of 
pancreatic enzyme supplementation, which is fundamental in the management of 
carbohydrate intolerance in CF, should not be overlooked. The benefit of a macro-
nutrient  ‘pre-load’,  and  efficacy, tolerability and long term safety of incretin-based 


















Fig 1. Gastric emptying of a meal in healthy subjects (n= 6) and CF patients (with 
and without pancreatic enzyme replacement therapy (PERT), n=5). Results 
represent means ± SE. Emptying was faster in CF with placebo than in healthy 
subjects (P<0.001, group-by-time interaction; ^, points of significant difference). 
PERT normalised gastric emptying compared with placebo in CF patients (P<0.001, 
treatment-by-time interaction; #, points of significant difference). Reprinted from Kuo 
et al [41], with permission. 
Fig 2. A. Plasma blood glucose, B. insulin, C. insulin-to glucose ratio, D. glucagon, 
E. GLP-1, and F. GIP concentrations in CF patients with and without pancreatic 
enzyme replacement therapy (PERT) and in healthy subjects after a mashed potato 
meal. Results represent mean ± SE. A, Blood glucose was higher in CF with placebo 
than in healthy subjects (P<0.001, group-by-time interaction; ^, points of significant 
difference). In CF patients PERT lowered blood glucose (P<0.001, treatment-by-time 
interaction; #, points of significant difference). B, Insulin concentrations did not differ 
between the groups. C, Insulin-to-glucose ratio was lower in CF patients than healthy 
subjects (P <0.05, group effect), and this did not improve with PERT. D, Glucagon 
concentrations did not differ between CF patients and healthy subjects but tended in 
CF patients to be higher after PERT (P=0.08, treatment effect). E, GLP-1 was lower 
in CF patients than healthy subjects (P<0.01, group effect), and this deficiency was 
completely reversed with PERT. F, GIP concentrations were lower in CF patients 
than in healthy subjects (P<0.001, group-by-time interaction; ^, points of significant 
difference). PERT increased plasma GIP secretion in CF patients (P<0.001, 
treatment-by-time interaction; # points of significant difference), but GIP remained 
lower than in healthy subjects (P<0.01, group-by-time interaction; *, points of 
significant difference). Reprinted from Kuo et al [41], with permission. 
  
Fig 3. A. Plasma blood glucose, B. GLP-1, C. GIP, D. insulin, E. insulin-to- glucose 
ratio, F. and glucagon concentrations in CF patients with placebo and PERT and in 
healthy controls after a high fat pancake meal. Results represent mean ± SE. A, 
Blood glucose was higher in CF with placebo than controls (P < 0.0001). PERT 
partially normalised blood glucose levels (P = 0.0002). B, iAUC GLP-1 was lower in 
CF than controls (P = 0.04), and normalised with PERT. C, iAUC GIP was lower in 
CF than controls (P 0.003), and normalised with PERT. D, Insulin concentrations 
were lower in CF than controls (P = 0.02) and did not normalise with PERT (P = 0.4). 
D, Insulin-to-glucose ratio was lower in CF than controls and did not normalise with 
PERT (P = 0.3). E, Glucagon concentrations were similar between CF and controls 
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